Scientific Board


The value of MedSIR lies in its ability to bring together the top experienced minds in the domain of Oncology along with identifying rising stars worldwide in order to guarantee top-level clinical trial designs that significantly and positively impact patient lives. This is a never-ending and evolving process that relies on international networking and an active presence in the four corners of the globe.

Scientific Board

«The value of MedSIR lies in its ability to bring together the top experienced minds in the domain of Oncology -and other Areas- along with identifying rising stars worldwide»

Our Core Network of Experts is made up of Drs. Antonio Llombart, Javier Cortés, Carlos Barrios, Xavier Pivot and Sunil Verma. Not only do strategic ideas continuously originate from the minds of these experts, but they, and others, also play the key role of expert reviewers of ideas originating from external Oncologists. The geographical reach, the many years of top level experience, the ability to understand current market trends and predict future ones, and their everyday contact with patients around the world all help to add an invaluable touch to MedSIR clinical trials, studies, and projects.

  • A. Llombart

    Dr. Antonio Llombart MD, PhD is Chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain and founding partner of Medica Scientia Innovation Research (MedSIR).

    He received his medical training in Pamplona and Valencia, finalizing a Medical Oncology degree from the University Hospital in Valencia. After his fellowship period (1994 to 1997) in the Breast Cancer Unit at Institute Gustave Roussy (Villejuif, France) focusing on new drugs (phase I and II studies), he became a medical staff member for two years in this french institution. Upon his return to Valencia, he chaired the Breast Cancer Research Unit at the Instituto Valenciano de Oncologia and, later, at the Medical Oncology Service of the University Hospital Arnau de Vilanova in Lleida, Spain, with a multidisciplinary scientific clinical unit made up of pharmacologists, surgeons, pathologists and biologists working with cytotoxic and molecular agents both in human and animal models. His main current focus is on translational clinical trials and correlative science in the neoadjuvant management of breast cancer patients.

    He is an active member of the Spanish and European clinical oncology community, working together with many international co-operative groups (BIG, GEICAM, SOLTI) and designing innovative clinical trials. He is also a Board Member of the Spanish Society of Medical Oncology.

    Antonio is also en expert consultant for several pharmaceutical companies (Eli Lilly, Novartis, Pfizer Oncology and Boehringer Ingelheim, Pierre Fabre) as well as the Institut National du Cancer (INCA), Paris, France. His contributions, as a member of the International Scientific Committee, in several pivotal international studies in breast cancer (P024, ZO-FAST) have helped to develop new drugs and, also, new therapeutical strategies.

    He is a member of Editorial Board of the journal Oncologie, La revue francophone de formation en Oncologie and author of more than 70 peer-reviewed publications.

  • J. Cortés

    Head, Breast Cancer and Gynecological tumours Ramón y Cajal University Hospital Oncology Department, Madrid, SP
    Head, Breast Cancer Program, IOB Insititute of Oncology, Madrid and Barcelona, SP
    Clinical Investigator, Breast Cancer Research Program Vall d’Hebron Institute of Oncology, Barcelona, SP

    Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specialising in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associated Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr. Cortés was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he has worked in the Department of Medical Oncology at the Hospital Vall d’Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in New Drugs Development. Dr. Cortés was the Head of the Breast Cancer Program and the Melanoma Unit from July 2006 to August 2015. From September 2015, he is Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid, Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology, and Head of Breast Cancer Program, IOB Institute of Oncology, Madrid and Barcelona, Spain.

    In addition to his medical specialties, he has two masters’ degree in “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.

    Dr. Cortes is the author of more than 200 publications, especially about breast tumours and new drugs and more than 500 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.

    Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), American Association for Cancer research (AACR) and a member of the Scientific Committee of the European Society of Medical Oncology.

    Selected Publications:

    • Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortés J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J. “p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer”. J Natl Cancer Inst 2007; 99: 628-38.
    • Cortés J, Di Cosimo S, Climent M, et al. Non-pegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel and Trastuzumab in HER2 Overexpressing Breast Cancer: A Multicenter Phase I/II Study. Clin Cancer Res 2009; 15: 307-14.
    • Cortés J, Baselga J. How to Treat Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Amplified Breast Cancer. J Clin Oncol 2009; 27: 5492-94.
    • Baselga J, Gelmon K, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortés J, Mcnally V, Ross G, Fumoleau P, Gianni L. A Phase II Trial of Pertuzumab and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer That Had Progressed During Prior Trastuzumab Therapy. J Clin Oncol 2010; 28: 1138-44.
    • Gianni L, Llado A, Bianchi G, Cortés J, et al. Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, A Her2 Dimerization Inhibitor, In Patients With Her2-Negative Metastatic Breast Cancer. J Clin Oncol 2010; 28: 1131-37.
    • Leyland-Jones B, Colomer R, Trudeau M, Wardley A, Latreille J, Cameron D, Cubedo R, Al-Sakaff N, Feyereislova A, Catalani O, Fukushima Y, Brewster M, Cortés J. An Intensive Loading Dose of Trastuzumab Achieves Higher Than Steady-State Serum Concentrations and Is Well Tolerated. J Clin Oncol 2010; 28: 960-66.
    • Miles M, Chan A, Dirix L, Cortés J, et al. Phase III Study of Bevacizumab plus Docetaxel Compared with Placebo plus Docetaxel for the First-line Treatment of HER2-negative Metastatic Breast Cancer. J Clin Oncol 2010; 28: 3239-47.
    • Cortés J, Vahdat L, Blum J, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with locally advanced or metastatic breast cancer, previously treated with an anthracycline, a taxane, an capecitabine. J Clin Oncol 2010; 28:3922-8.
    • Cortés J, Saura C, Bellet M, et al. HER2 and hormone receptor-positive breast cancer-blocking the right target. Nat Rev Clin Oncol 2011; 8:307-11
    • Cortés J, O’Shaughnessy J, Loesch D, et al. A Phase III open-label randomised study (EMBRACE) of eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer. Lancet 2011; 377:914-23
    • Scaltriti M, Eichhorn PJ, Cortés J, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA 2011; 108:3761-6
    • Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortés J, et al. First-Line Treatment of Advanced Breast Cancer with Sunitinib in Combination with Docetaxel versus Docetaxel Alone – Results of a Prospective, Randomized Phase III Study. J Clin Oncol 2012; 30:921-9
    • Cortés J, Fumoleau P, BianchiG, et al. Pertuzumab Monotherapy Following Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients with Advanced HER2-Positive Breast Cancer. J Clin Oncol 2012; 30:1594-600
    • Baselga J, Cortes J, Sung-Bae-K, et al. Pertuzumab plus Trastuzumab plus Docetaxel in Metastatic Breast Cancer. N Engl J Med 2012; 366:109-119
    • Scaltriti M, Dawood S, Cortes J. Molecular Pathways: Targeting Hsp90, who benefits and who does not. Clin Cancer Res 2012; 18(17):4508-13
    • Cortes J, Calvo E, González-Martín E, et al. Progress against Solid Tumors in Danger: The Metastatic Breast Cancer Example. J Clin Oncol 2012; 30(28): 3444-7
    • Somlo G, Atzori F, Strauss LC, Geese W, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT, Cortes J. Dasatinib Plus Capecitabine for Advanced Breast Cancer: Safety and Preliminary Efficacy in Phase I Study CA180004. Clin Cancer Res. 2013 1;19(7):1884-93
    • Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schenneeweiss A, Knott A, Clark E, Ross G, Benynes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomized, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14(6):461-71
    • Schnneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortes J. Pertuzumab Plus Trastuzumab in Combination With Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients With HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84
    • J.Cortes, J.Baselga, Y.-H.Im, S.-A.Im, X.Pivot, G.Ross, E.Clark, A.Knott, S.M.Swain. Health-related quality of life assessment in CLEOPATRA, a Phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 2013 ;24(10):2630-5
    • Cortes J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, Seoane. J. New Approach to Cancer Therapy Based on a Molecularly Defined Cancer Classification. CA Cancer J Clin. 2014; 64(1):70-4
    • Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, ciruelos E, Ferrero JM, Sheneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J. Pertuzumab, Trastuzumab, Docetaxel in HER2-Positive Metastatic Breast Cancer. New Eng J Med 2015 Feb 19:372 (8): 724-34
    • Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients with locally advanced or Metastatic Breast Cancer Previously Treated with Antracycline and a Taxane. J Clin Oncol 2015 Feb 20;33(6): 594-601
  • C.Barrios

    Dr. Carlos Henrique Barrios has been a Professor of the Internal Medicine Department and the Director of the Oncology Research Unit at Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) in Porto Alegre, Brazil, since 1991. Currently, Dr. Barrios is also the Director of the Cancer Institute at the Hospital Mãe de Deu in Porto Alegre and the Director of the Latin American Clinical Oncology Research Group (GLICO).

    Dr. Barrios graduated from the Pontifícia Universidade Católica do Rio Grande do Sul in 1979. After training in Internal Medicine at Jackson Memorial Hospital (University of Miami, Florida) from 1982-1985, he went on to complete a Hematology and Oncology Fellowship at Barnes/Jewish Hospitals (Washington University, St. Louis, Missouri) from 1985-1988. He was a Clinical Instructor in the Department of Medicine at Washington University in 1989. He has obtained the following certifications: ECFMG (1978); VQE (1981); FLEX; Board of Medical Examiners, Florida (1985); American Board of Internal Medicine (1986); American Board of Oncology (1987); and American Board of Hematology (1988).

    Dr. Barrios has been an Adjuvant Assistant Professor of the Department of Medicine at the University of Miami School of Medicine since 1990 and the local representative of the William J. Harrington Latin American Program. He has participated in many clinical trials over the last 10 years. He has numerous publications in professional medical journals and is often invited as a speaker at cancer congresses worldwide.

  • S. Verma

    Dr. Sunil Verma, MD, MSEd, FRCPC is an Associate Professor at the University of Toronto and a Medical Oncologist at the Sunnybrook Odette Cancer Centre. He completed his medical degree and postgraduate training in Internal Medicine and Medical Oncology at the University of Alberta in Canada. Dr. Verma also completed a fellowship in breast cancer at the University of Toronto and a Masters degree in Medical Education at the University of Southern California.

    Dr. Verma is internationally recognized for his research and education leadership in breast and lung cancer and is the Chair of Breast Medical Oncology at Sunnybrook Odette Cancer Centre. His research interests include reducing the toxicity of systemic treatment, developing novel therapies for breast and lung cancer, and medical education. He is the principal investigator for many trials in breast and lung cancer including an international Phase III trial in breast cancer. He has led and created numerous innovative educational projects in Oncology and has won several teaching and mentoring awards. He has authored or co-authored articles appearing in such publications as the Journal of Clinical Oncology, Cancer, The Oncologist, and Lancet Oncology.

  • X. Pivot

    Dr. Xavier Pivot graduated in Medical Oncology from the University of Nice-Sophia-Antipolis in 1996 and later continued his studies in pharmacology at the University of Paris and Marseille, obtaining the degree of Doctor of Pharmacology.

    He began his career as a deputy at the Breast Pathology Service of the Institut Gustave Roussy in Paris and later at the Centre Antoine Lacassagne in Nice. For five years, between 2002 and 2007, he was part of the French Committee of Oncology Drug Approval (GTOH-Affasps).

    He has chaired the research group in breast cancer at the Institut National du Cancer (INCA) for the last seven years and is an active member of U645 INSERM (National Institute of Medical Scientific Research) in the fields of Immunology and Oncology. Moreover, since 2005, he has served as the Medical Director of the Institut du Cancerologie Regional Federatif.

    Breast and head and neck cancer and the pharmacological aspects related to oncology have marked the outlines of their work in research, authoring and/or co-authoring more than 140 scientific references.

    He is currently Professor at the Université de Franche-Comté where he chairs the Department of Medical Oncology, Hematology and Radiation CHU Besançon – Hôpital Jean Minjoz.